Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832595 · ClinicalTrials.gov registry record · NA
Kidney Coordinated Health Management Partnership
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 1,596
- Enrollment target
NCT03832595: Completed NA study, sponsored by University of Pittsburgh.
NCT03832595 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 1,596 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03832595, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,596 participants
- Enrollment target
Study Summary
As part of a 42-month pragmatic, cluster randomized trial in 1,650 primary care patients with high-risk Chronic Kidney Disease (CKD), the investigators will test the effectiveness of a multifaceted Electronic Health Record (EHR)-based Population Health Management (PHM) intervention that targets improvements in the delivery of evidence-based CKD care.
Primary Outcome
The outcome measure is occurrence of renal failure event and is defined as a greater than or equal to 40% decline in eGFR or occurrence of End Stage Renal Disease. The 40% decline in renal failure is a well accepted endpoint for renal failure in clinical trials and is approved by the FDA. eGFR decline will be adjudicated based on the baseline creatinine and eGFR determined from the CKD-epidemiology (CKD-EPI) equation and measured routinely in clinical practice. All eGFR values within 6-month wi
Interventions
- OTHER Usual Care
- OTHER EHR-based PHM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,596 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2023-07-31 |
| Phase | NA |
What the finished NCT03832595 record still lists
NCT03832595 is an interventional study that assigns participants to a tested intervention. Its 1,596 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT03832595 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03832595 about?
NCT03832595 is a clinical study titled "Kidney Coordinated Health Management Partnership". As part of a 42-month pragmatic, cluster randomized trial in 1,650 primary care patients with high-risk Chronic Kidney Disease (CKD), the investigators will test the effectiveness of a multifaceted Electronic Health Record (EHR)-based Population Health Management (PHM) intervention that targets impr...
What is the current status of trial NCT03832595?
This trial is currently completed. It is a NA study. The enrollment target is 1,596 participants. The study started on 2019-05-01. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT03832595?
The interventions under investigation include: Usual Care (OTHER), EHR-based PHM (OTHER).
Who is sponsoring clinical trial NCT03832595?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03832595's enrollment target sits among peer trials
1,596 64th of 2000 higher than 1,937 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05243797 · 1,594 participants · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI